Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 100427-26-7 Chemical Structure| 100427-26-7

Structure of Lercanidipine
CAS No.: 100427-26-7

Chemical Structure| 100427-26-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Lercanidipine is a third-generation, lipophilic, blood-brain barrier-penetrant, orally active dihydropyridine calcium channel blocker with a pIC50 of 7.74 (converted from micromolar concentration). Lercanidipine has prolonged antihypertensive effects and renal and neuroprotective properties, as well as antioxidant, anti-inflammatory, and anti-apoptotic characteristics. Lercanidipine is used in cardiovascular and neurological research.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Lercanidipine

CAS No. :100427-26-7
Formula : C36H41N3O6
M.W : 611.73
SMILES Code : O=C(C1=C(C)NC(C)=C(C(OC)=O)C1C2=CC=CC([N+]([O-])=O)=C2)OC(C)(C)CN(CCC(C3=CC=CC=C3)C4=CC=CC=C4)C
MDL No. :MFCD00867978

Safety of Lercanidipine

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301
Precautionary Statements:P264-P270-P301+P310+P330-P405-P501
Class:6.1
UN#:2811
Packing Group:

Related Pathways of Lercanidipine

MAPK
pyroptosis
TLR

Isoform Comparison

Biological Activity

Target
  • Calcium Channel

In Vitro:

Cell Line
Concentration Treated Time Description References
GBM1 cells 7 μM Inhibited GLT8D1 expression, reduced CD133 and β-catenin protein stability PMC9433395
Chang (normal liver cells) 10 μM 24 h Lercanidipine did not significantly increase the cytotoxicity of Bortezomib in normal cells PMC6941136
MCF-10A (normal breast cells) 10 μM 24 h Lercanidipine did not significantly increase the cytotoxicity of Bortezomib in normal cells PMC6941136
RPMI-8226 (multiple myeloma cells) 10 μM 24 h Lercanidipine enhances the cytotoxicity of Bortezomib in cancer cells, inducing paraptosis-associated cell death PMC6941136
BxPC-3 (pancreatic cancer cells) 10 μM 24 h Lercanidipine enhances the cytotoxicity of Bortezomib in cancer cells, inducing paraptosis-associated cell death PMC6941136
NCI-H460 (lung cancer cells) 10 μM 24 h Lercanidipine enhances the cytotoxicity of Bortezomib in cancer cells, inducing paraptosis-associated cell death PMC6941136
SNU-668 (stomach cancer cells) 10 μM 24 h Lercanidipine enhances the cytotoxicity of Bortezomib in cancer cells, inducing paraptosis-associated cell death PMC6941136
SNU-475 (liver cancer cells) 10 μM 24 h Lercanidipine enhances the cytotoxicity of Bortezomib in cancer cells, inducing paraptosis-associated cell death PMC6941136
MDA-MB 435S (breast cancer cells) 10 μM 24 h Lercanidipine enhances the cytotoxicity of Bortezomib in cancer cells, inducing paraptosis-associated cell death PMC6941136
A172GSC cells 7 μM Inhibited GLT8D1 expression, reduced CD133 and β-catenin protein stability PMC9433395
U251GSC cells 7 μM Inhibited GLT8D1 expression, reduced CD133 and β-catenin protein stability PMC9433395
GSC11 cells 7 μM Inhibited GLT8D1 expression, reduced CD133 and β-catenin protein stability PMC9433395
OC-1 cells 0.3 to 2.5 µM 24 h To evaluate the antioxidative effect of Lercanidipine on OC-1 cell viability, results showed that 0.3 to 2.5 µM Lercanidipine significantly enhanced cellular viability PMC10967582
CHO cells (expressing Ca v1.2b subunit) 10^-7 M 600 seconds To study the inhibitory effect of (S)-lercanidipine on vascular Ca v1.2b subunit, showing IC50=1.8×10^-8 M, Hill coefficient nH=0.8, indicating higher selectivity for the vascular isoform. PMC1574954
CHO cells (expressing Ca v1.2a subunit) 10^-7 M 600 seconds To study the inhibitory effect of (S)-lercanidipine on cardiac Ca v1.2a subunit, showing IC50=3.3×10^-8 M, Hill coefficient nH=2.3, indicating overlap between agonistic and antagonistic effects. PMC1574954
Primary lung cancer cells 10 μM 24 h Inhibited the expression of PD-L1 PMC7838064
NCI-H460 cells 10 μM 24 h Inhibited the transcriptional levels of PD-L1 PMC7838064
NCI-H1299 cells 10 μM 24 h Inhibited the transcriptional levels of PD-L1 PMC7838064
Vero cells 10 μM 1 h Screening for LUJV entry inhibitors PMC8675865

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice Xenograft tumor models Tail vein injection 5 mg/kg Twice every week for four weeks Suppressed tumor growth, reduced GLT8D1 and CD133 expression, increased apoptosis markers PMC9433395
White New Zealand rabbits Atherosclerotic lesions induced by cholesterol feeding Subcutaneous injection 0.3, 1, and 3 mg/kg Once a week for 10 weeks Significantly reduced intimal hyperplasia and aortic fatty streak area in a dose-dependent manner PMC1565732
C57BL/6J mice Noise-induced hearing loss model Intraperitoneal injection 6 mg/kg 1 hour before noise exposure and once daily on days 1, 2, and 3 post-exposure To investigate the protective effect of Lercanidipine against noise-induced hearing loss, results showed that Lercanidipine significantly attenuated the elevation of hearing thresholds and preserved OHC survival in the basal turn PMC10967582

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00424801 Microvascular Angina ... More >> Hypertension Less << Not Applicable Terminated(Due to recent findi... More >>ngs relating MRI contrast to nephrogenic systemic fibrosis) Less << December 2008 Denmark ... More >> Aarhus Hospital Aarhus, Denmark, 8000 Less <<
NCT00741585 Essential Hypertension ... More >> Cardiovascular Disease Stroke Chronic Kidney Disease Less << Phase 4 Completed - Spain ... More >> CS Friol Friol, Lugo, Spain, 27220 CS Baiona Baiona, Pontevedra, Spain, 36300 CS Bueu Bueu, Pontevedra, Spain, 36930 CS A Estrada La Estrada, Pontevedra, Spain, 26680 CS A Guarda La Guardia, Pontevedra, Spain, 36780 CS Valmiñor Nigran, Pontevedra, Spain, 36250 CS Panxón Nigrán, Pontevedra, Spain, 36340 CS Tomiño Tomiño, Pontevedra, Spain, 36200 Bioengineering & Chronobilogy Labs., University of Vigo Vigo, Pontevedra, Spain, 36200 Hospital do Meixoeiro Vigo, Pontevedra, Spain, 36200 CS Calle Cuba Vigo, Pontevedra, Spain, 36202 CS A Doblada Vigo, Pontevedra, Spain, 36205 CS Coia Vigo, Pontevedra, Spain, 36209 CS Sardoma Vigo, Pontevedra, Spain, 36214 CS Teis Vigo, Pontevedra, Spain, 36216 CS Vilaboa Vilaboa, Pontevedra, Spain, 36141 CS San Roque Vilagarcía De Arousa, Pontevedra, Spain, 36600 CS Fingoi Lugo, Spain, 27002 Complexo Hospitalario Universitario de Ourense Orense, Spain, 32005 CS Lerez Pontevedra, Spain, 36156 Less <<
NCT02594410 Hypertension Phase 4 Completed - China ... More >> Fuwai Hospital Beijing, China Less <<
NCT02415192 - Unknown November 2016 Korea, Republic of ... More >> LG Life Science Recruiting Seoul, Jongno gu, Korea, Republic of, 110-783 Contact: Hye jin Yoon Less <<
NCT03195023 Renal Insufficiency, Chronic ... More >> Proteinuria Less << Phase 4 Recruiting June 2021 Spain ... More >> Gregorio Maranon Hospital Recruiting Madrid, Spain, 28007 Contact: Maria Angeles Goicoechea, PhD, MD    0034609838684    marian.goicoechea@gmail.com    Contact: Ana María García, MD    0034676611045    anamgarciaprieto@gmail.com Less <<
NCT01211314 Hypertension Phase 4 Terminated(sponsor decision) - Israel ... More >> Clalit Health Services Hertsliyah, Hasharon, Israel Less <<
NCT01180413 Essential Hypertension ... More >> High Blood Pressure Less << Phase 4 Completed - Denmark ... More >> Aarhus University Hospital - dept. cardiology (A) Aarhus, Denmark, 8000 Less <<
NCT01093807 Essential Hypertension Phase 2 Completed - France ... More >> Hôpital de la Pitié-Salpétrière Paris, France Less <<
NCT00160498 Hypertension COMPLETED 2025-08-05 -
NCT01928628 Hypertension Phase 3 Completed - Korea, Republic of ... More >> Seoul National University Hospital Seoul, Korea, Republic of Less <<
NCT01122251 Essential Hypertension Phase 2 Completed - Korea, Republic of ... More >> 23 sites in Korea Seoul, Busan etc., Korea, Republic of Seoul National University Hospital Seoul, Korea, Republic of Less <<
NCT01520285 Hypertension Phase 4 Completed - China ... More >> Shanghai First People's Hospital Shanghai, China, 200000 Less <<
NCT03497156 Obesity, Morbid RECRUITING 2025-10-26 St. Olavs University Hospital,... More >> Trondheim, Norway Less <<
NCT00564057 HIV Infections ... More >> Hypertension Less << Phase 4 Unknown September 2009 Italy ... More >> University of Insubria, Department of Clinical Medicine Recruiting Varese, Italy, 21100 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.63mL

0.33mL

0.16mL

8.17mL

1.63mL

0.82mL

16.35mL

3.27mL

1.63mL

References

 

Historical Records

Categories